Renalytix plc

("Renalytix" or the "Company")

Directorate change

LONDON and SALT LAKE CITY - October 24, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that Timothy Scannell has stepped down from his role as independent Non-Executive Director of Renalytix effective as of October 18, 2023, to pursue other opportunities. 

James McCullough, CEO of Renalytix plc, commented: "It has been a wonderful learning experience to work alongside Tim for the past 18 months. He has been a significant contributor to Renalytix, and I would like to thank him for all his efforts on the Board."

For further information, please contact:

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.